Sudan Loganathan

Stock Analyst at Stephens & Co.

(0)
# 4450
Out of 5,352 analysts
36
Total ratings
40.74%
Success rate
-11.94%
Average return
17 Stocks
Name Action PT Current % Upside Ratings Updated
BPMC Blueprint Medicines
Downgrades: Equal-Weight
150 135
127.64 5.77% 3 Jun 3, 2025
ELEV Elevation Oncology
Downgrades: Equal-Weight
5 5
0.3 1566.67% 4 Mar 24, 2025
IMNM Immunome
Reiterates: Overweight
30 30
9.27 223.62% 2 Mar 20, 2025
CPRX Catalyst Pharmaceuti...
Reiterates: Overweight
33 33
24.91 32.48% 2 Feb 27, 2025
ADCT ADC Therapeutics
Maintains: Overweight
6 8
3.58 123.46% 2 Feb 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
50 50
21.66 130.84% 2 Feb 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Equal-Weight
29 29
42.64 -31.99% 4 Feb 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Equal-Weight
15 15
8.3 80.72% 2 Jan 22, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
31 31
12.1 156.2% 3 Jan 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
60 60
43.58 37.68% 2 Jan 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
5 5
1.68 197.62% 2 Nov 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Equal-Weight
4
1.48 170.27% 1 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
55
6.99 686.84% 1 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
13
1.33 877.44% 1 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
25 25
16.18 54.51% 2 Aug 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
5 5
0.34 1370.59% 2 May 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
20
2.12 843.4% 1 May 14, 2024